KW 007
Alternative Names: KW-007Latest Information Update: 15 Oct 2023
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class Antineoplastics; Interleukins
- Mechanism of Action Interleukin 15 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bladder cancer
Most Recent Events
- 06 Sep 2023 Phase-I clinical trials in Bladder cancer in unknown location (Parenteral), prior to September 2023 (Kawin pipeline, September 2023)